D. Boral Capital Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They currently have a $21.00 price objective on the stock. D. Boral Capital’s target price suggests a potential upside of 364.60% from the stock’s previous close.

A number of other equities research analysts have also weighed in on the stock. HC Wainwright boosted their target price on shares of Trevi Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a research note on Thursday, December 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Trevi Therapeutics in a report on Thursday, December 12th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $9.31.

Trevi Therapeutics Stock Up 4.9 %

TRVI opened at $4.52 on Monday. The stock has a market capitalization of $347.43 million, a price-to-earnings ratio of -10.27 and a beta of 0.88. The firm has a 50 day moving average price of $4.09 and a 200-day moving average price of $3.41. Trevi Therapeutics has a twelve month low of $2.30 and a twelve month high of $5.05.

Hedge Funds Weigh In On Trevi Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of TRVI. Frazier Life Sciences Management L.P. raised its stake in shares of Trevi Therapeutics by 44.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company’s stock worth $43,939,000 after buying an additional 3,283,684 shares during the period. Point72 Asset Management L.P. bought a new stake in Trevi Therapeutics during the 4th quarter worth approximately $17,099,000. Vivo Capital LLC lifted its holdings in Trevi Therapeutics by 116.3% during the fourth quarter. Vivo Capital LLC now owns 3,487,903 shares of the company’s stock valued at $14,370,000 after purchasing an additional 1,875,000 shares in the last quarter. Woodline Partners LP boosted its position in shares of Trevi Therapeutics by 429.9% in the fourth quarter. Woodline Partners LP now owns 3,212,597 shares of the company’s stock worth $13,236,000 after purchasing an additional 2,606,370 shares during the period. Finally, MPM Bioimpact LLC boosted its position in shares of Trevi Therapeutics by 101.2% in the fourth quarter. MPM Bioimpact LLC now owns 3,094,896 shares of the company’s stock worth $12,751,000 after purchasing an additional 1,556,379 shares during the period. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.